Related Experiment Video
Updated: Aug 19, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Blockade of epidermal growth factor receptor (EGFR) activity
Antonio Jimeno1, Manuel Hidalgo
1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Bunting-Blaustein Cancer Research Building, Room 1M88, 1650 Orleans Street, Baltimore, MD 21231-1000, USA.
Abstract:
The rapidly expanding knowledge of the pathogenesis of cancer at the molecular level is providing new targets for drug discovery and development. The key role that EGFR plays in the intracellular transduction of environmental variations and the maintenance of cellular homeostasis explains the dependence that many tumor types have on this pathway, and the pivotal role that it plays in the development of malignant features such as uncontrolled proliferation, augmented invasion, and the ability to escape apoptosis. An enormous body of knowledge has been gathered in the past 20 years that has enabled the development of rationally designed EGFR-targeted therapies, and the results of their clinical evaluation are now becoming available. The lack of positive results of some of these trials has highlighted the need for a robust preclinical knowledge in order to efficiently select patients for therapy, and have prompted the implementation of novel trial designs with rational endpoints.
Insights
Understanding cancer
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Epidermal Growth Factor Receptor (EGFR) is crucial for cell homeostasis and tumor development.
- EGFR pathway drives cancer proliferation, invasion, and apoptosis evasion.
- Many tumors depend on the EGFR pathway.
Purpose of the Study:
- To review the development of EGFR-targeted therapies.
- To discuss the clinical evaluation of these therapies.
- To highlight the need for improved preclinical models and trial designs.
Main Methods:
- Review of molecular pathogenesis of cancer.
- Analysis of EGFR's role in cancer.
- Evaluation of clinical trial outcomes for EGFR-targeted therapies.
Main Results:
- Rational drug design has yielded EGFR-targeted therapies.
- Clinical trial results show variable efficacy.
- Need for better patient selection and novel trial designs is evident.
Conclusions:
- EGFR is a key target in cancer therapy.
- Preclinical research is vital for selecting patients for EGFR-targeted treatments.
- Optimized clinical trial designs are necessary for advancing EGFR-targeted therapy.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Receptor Tyrosine Kinases
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Clinical Applications of Epidermal Stem Cells